Claims for Patent: 9,051,617

Summary for Patent: 9,051,617

Title:	Markers for breast cancer
Abstract:	Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.
Inventor(s):	Cox; David (Belmont, CA), Ballinger; Dennis (Menlo Park, CA), Ponder; Bruce (Cambridge, GB), Easton; Doug (Welwyn, GB)
Assignee:	Cambridge Enterprise Limited (Cambridge, GB)
Application Number:	12/890,272
Patent Claims:	1. A method of determining the identity of the alleles of fewer than 1,000 single nucleotide polymorphisms (SNPs) in a woman subject selected from the group of subjects consisting of women in need of screening for breast cancer susceptibility to produce a polymorphic profile of the selected woman subject in need of breast cancer screening, comprising (i) obtaining a biological sample comprising a genome from the selected woman subject in need of breast cancer screening; (ii) selecting for allelic identity analysis at least a SNP located at rs2981582 within the nucleotide sequence of an intron of a Fibroblast Growth Factor Receptor 2 (FGFR2) gene, and a SNP located at rs889312 within the genome of the selected woman subject in need of breast cancer screening; (iii) assaying, with a probe or a primer, whether a) the selected woman subject is homozygous or heterozygous for an adenine (A) or a guanine (G) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene in the biological sample of step (i), wherein if the assaying is with a primer, then the assaying comprises (1) hybridizing a primer to a nucleic acid having the sequence of a region proximal to the SNP located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene or (2) hybridizing a primer to a nucleic acid having the sequence of an allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene, and if the assaying is with a probe, then the assaying comprises (1) hybridizing a probe to a nucleic acid having the sequence of the adenine (A) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene and (2) hybridizing a probe to a nucleic acid having the sequence of the guanine (G) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene, and b) the selected woman subject is homozygous or heterozygous for a cytosine (C) or an adenine (A) allele located at rs889312 within the nucleotide sequence of the genome in the biological sample of step (i), wherein if the assaying is with a primer, then the assaying comprises (1) hybridizing a primer to a nucleic acid having the sequence of a region proximal to the SNP located at rs889312 within the nucleotide sequence of the genome of the woman subject or (2) hybridizing a primer to a nucleic acid having the sequence of an allele located at rs889312 within the nucleotide sequence of the genome of the woman subject, and if the assaying is with a probe, then the assaying comprises (1) hybridizing a probe to a nucleic acid having the sequence of the cytosine (C) allele located at rs889312 within the nucleotide sequence of the genome of the woman subject and (2) hybridizing a probe to a nucleic acid having the sequence of the adenine (A) allele located at rs889312 within the nucleotide sequence of the genome of the woman subject, and (iv) producing the polymorphic profile of the selected woman subject in need of breast cancer screening based on the identity of the alleles assayed in step (iii), wherein fewer than 1,000 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 1,000 SNPs are assayed in step (iii). 2. The method of claim 1, wherein the selected woman subject in need of screening for breast cancer susceptibility has at least two first degree relatives who have had breast cancer. 3. The method of claim 2, wherein the two first degree relatives of the selected woman subject in need of screening for breast cancer susceptibility are siblings of the woman subject in need of screening for breast cancer susceptibility. 4. The method of claim 2, wherein one of the first degree relatives of the selected woman subject in need of screening for breast cancer susceptibility is the mother of the woman subject in need of screening for breast cancer susceptibility. 5. The method of claim 1, wherein the selected woman subject in need of screening for breast cancer susceptibility has one first and two second degree relatives who have had breast cancer. 6. The method of claim 5, wherein the first degree relative of the selected woman subject in need of screening for breast cancer susceptibility is the mother of the selected woman subject in need of screening for breast cancer susceptibility. 7. The method of claim 1, wherein the selected woman subject in need of screening for breast cancer susceptibility is not known to have developed cancer. 8. The method of claim 1, wherein the selected woman subject in need of screening for breast cancer susceptibility does not have a BRCA1/2 mutation. 9. The method of claim 1, wherein the selected woman subject in need of screening for breast cancer susceptibility is postmenopausal. 10. The method of claim 1, further comprising assaying, with a probe or a primer, the identity of an allele of a SNP which is located at rs13281615 in the genome of the selected woman subject in need of breast cancer screening by selecting for allelic identity analysis the allele which is located at rs13281615 within the genome of the selected woman subject in need of breast cancer screening and determining whether the selected woman subject is homozygous or heterozygous for a guanine (G) or an adenine (A) located at rs13281615 within the nucleotide sequence of the genome in the biological sample of step (i). 11. The method of claim 10, further comprising assaying, with a probe or a primer, the identity of an allele of a SNP which is located at rs3817198 within the nucleotide sequence of an intron of a Lymphocyte-Specific Protein 1 (LSP1) gene of the selected woman subject in need of breast cancer screening by selecting for allelic identity analysis the allele which is located at rs3817198 within the nucleotide sequence of an intron of a LSP1 gene of the selected woman subject in need of breast cancer screening and determining whether the selected woman subject is homozygous or heterozygous for a cytosine (C) or an thymine (T) located at rs3817198 within the nucleotide sequence of the LSP1 gene in the biological sample of step (i). 12. The method of claim 1, wherein fewer than 100 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 100 SNPs are assayed in step (iii). 13. The method of claim 12, wherein fewer than 50 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 50 SNPs are assayed in step (iii). 14. The method of claim 13, wherein fewer than 25 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 25 SNPs are assayed in step (iii). 15. The method of claim 14, wherein fewer than 10 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 10 SNPs are assayed in step (iii). 16. The method of claim 10, wherein fewer than 50 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 50 SNPs are assayed in step (iii). 17. The method of claim 16, wherein fewer than 25 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 25 SNPs are assayed in step (iii). 18. The method of claim 11, wherein fewer than 50 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 50 SNPs are assayed in step (iii). 19. The method of claim 18, wherein fewer than 25 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 25 SNPs are assayed in step (iii).

Details for Patent 9,051,617

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-11-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-11-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-11-29